

DRUG AND ALCOHOL DEPENDENCE

Purpose and Scope

Drug and Alcohol Dependence is an international journal devoted to publishing original research, scholarly reviews, commentaries, and policy analyses in the areas of drug, alcohol, and tobacco use and dependence. Articles range from studies of the chemistry of substances of abuse, their actions at molecular and cellular sites, in vitro and in vivo investigations of their biochemical, pharmacological, and behavioral actions, laboratory-based and clinical research in humans, substance abuse treatment and prevention research, to studies employing methods from epidemiology, sociology, and economics. The rationale for this extensive coverage is the conviction that drug, alcohol, and tobacco use/dependence cannot be understood in their entirety from a single perspective and that without an understanding of other areas of research, studies by individual investigators may be limited. The goal of the journal is to provide researchers, clinicians, and policy makers access to material from all perspectives in a single journal in a format that is understandable and which has received rigorous editorial review. The hope of its Editors is to promote mutual understanding of the many facets of drug abuse to the benefit of all investigators involved in drug and alcohol research, and to facilitate the transfer of scientific findings to successful treatment and prevention practices. *Drug and Alcohol Dependence* is currently being distributed to all the members of The College on Problems of Drug Dependence, the oldest scientific organization in the United States concerned with the research on problems of drug dependence.

Types of Papers

1. **Full-length Reports** reporting original results of research within the field of drug, alcohol and tobacco use and dependence.
2. **Review Articles** of specialised topics within the scope of the journal. Authors who plan to submit reviews to the journal are advised to contact one of the editors to discuss the suitability of the proposed topic.
3. **Short Communications** reporting on research that has progressed to the stage where a preliminary publication is appropriate. The maximum length allowed will be 1500 words plus references and illustrations. There should be not more than 2 illustrations (figures or tables).

Drug and Alcohol Dependence is a signatory of the Farmington Consensus Statement which is published in its entirety in Volume 48 Issue 3. Submission of a paper to the journal will be taken as evidence that the authors have complied with the tenets set forth in that statement. When articles are submitted, a written statement that each listed author has contributed substantially to the work and concurs with the submission should be included. This implies that a copy of the final manuscript has been approved by all authors and tacitly and explicitly by the responsible authorities in the laboratories where the work was carried out. Authors should also assure the journal in a written statement that there is no known conflict of interest. If authors have any questions concerning a possible conflict of interest, they should consult the Editor prior to submission. Authors should reveal explicitly in the manuscript all funding sources that enabled the studies to be conducted and the manuscript prepared, and that the study was conducted with the appropriate ethical safeguards. Submission of a paper to *Drug and Alcohol Dependence* is also understood to imply that it has not previously been published and that it is not being published elsewhere, including in electronic form. The accepted abbreviation for *Drug and Alcohol Dependence* for bibliography citation is *Drug Alcohol Depend.* If accepted, the manuscript shall not be published elsewhere in the same form or electronically, in either the same or another language, without the consent of the Editor and Publisher. Authors should be aware that the journal has defined policies for response to attempted or actual instances of duplicate publication, plagiarism, or scientific fraud.

Editor-in-Chief: Eric C. Strain, M.D.,
Johns Hopkins University School of Medicine

Editorial Office Manager:
Andraya Dolbee

Associate Editors:

Behavioral Pharmacology
Craig R. Rush, Ph.D.,
University of Kentucky

Preclinical and Clinical Neurosciences
Linda Porrino, Ph.D.,
Wake Forest University School of Medicine

Comorbidity, Psychiatric Epidemiology, Etiology, Nosology and Genetics
Katherine M. Keyes, Ph.D.,
Columbia University

Services and Prevention, Technology Transfer, and Treatment
Jan Copeland, Ph.D.,
University of New South Wales

Etiology, Epidemiology, Prevention and Policy
Steffanie A. Strathdee, Ph.D.,
University of California, San Diego
Steven Shoptaw, Ph.D.,
University of California, Los Angeles

Tobacco and Nicotine, Health Disparities, Developmental Psychopathology
Adam M. Leventhal, Ph.D.,
University of Southern California

Human Psychopharmacology and Genetics
Eske Derks, Ph.D.,
Academic Medical Center, Amsterdam

Treatment and Services
Kyle Kampman, M.D.,
University of Pennsylvania

Neuropsychopharmacology and Treatment
Lin Lu, M.D., Ph.D.,
Peking University

DAD Fellow
Joseph Palamar, Ph.D., MPH,
New York University

Editorial Board:

F.J. Alvarez, Valladolid, Spain
J.C. Anthony, East Lansing, USA
M. Auriacombe, Bordeaux, France
R.L. Balster, Richmond, VA, USA
F.J.P.M. Bastos, Rio de Janeiro, Brazil
W.K. Bickel, Roanoke, VA, USA
K.T. Brady, Charleston, SC, USA
Z.D. Cooper, New York, New York, USA
J.F. Cubells, Atlanta, GA, USA
S. Darke, Kensington, NSW, Australia
L.C. Dierker, Middletown, CT, USA

M.E. Enslinger, Baltimore, MD, USA
M. Farré, Barcelona, Spain
M. Field, Liverpool, UK
P.M. Flynn, Ft. Worth, TX, USA
I.H.A. Franken, Rotterdam, The Netherlands
B.F. Grant, Rockville, MD, USA
O. Gureje, Ibadan, Nigeria
D.S. Hasin, New York, New York, USA
D.K. Hatsukami, Minneapolis, MN, USA
J.R. Havens, Lexington, Kentucky, USA
M.Y. Iguchi, Santa Monica, CA, USA
J. Kitanaka, Hyogo, Japan

H.R. Kranzler, Farmington, CT, USA
R.J. Lamb, San Antonio, TX, USA
S. Lukas, Belmont, MA, USA
A.T. McLellan, Philadelphia, PA, USA
M.E. Medina-Mora, Mexico City, Mexico
F.G. Moeller, Richmond, Virginia, USA
M. Munafò, Bristol, UK
T.C. Napier, Chicago, IL, USA
I.S. Obot, Geneva, Switzerland
V.R. Preedy, London, UK
K.L. Preston, Baltimore, MD, USA
A.J. Saxon, Seattle, WA, USA

J.L. Sorensen, San Francisco, CA, USA
I.P. Stolerman, London, UK
J. Strang, London, UK
D. Svikis, Richmond, VA, USA
R. Tarter, Pittsburgh, PA, USA
W. van den Brink, Amsterdam, The Netherlands
S.L. Walsh, Lexington, KY, USA
H.-U. Wittchen, Munich, Germany

Previous Editors:

Hans Halbach
Charles R. Schuster
Chris-Ellyn Johanson
Ian P. Stolerman
Robert L. Balster

© 2016, Elsevier Ireland Ltd. All rights reserved.

Publication information: *Drug and Alcohol Dependence* (ISSN 0376-8716). For 2016 Volumes 158–169 are scheduled for publication. Subscription prices are available upon request from the Publisher or from the Elsevier Customer Service Department nearest you or from this journal's website (<http://www.elsevier.com/locate/drugalcdep>). Further information is available on this journal and other Elsevier products through Elsevier's website: (<http://www.elsevier.com>). Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by standard mail (surface within Europe, air delivery outside Europe). Priority rates are available upon request. Claims for missing issues should be made within six months of the date of dispatch.

Processed at Thomson Digital, Gangtok (India)